Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Non-Current Debt: 2010-2025

Historic Non-Current Debt for Cytokinetics (CYTK) over the last 10 years, with Sep 2025 value amounting to $158.7 million.

  • Cytokinetics' Non-Current Debt rose 70.66% to $158.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $158.7 million, marking a year-over-year increase of 70.66%. This contributed to the annual value of $93.2 million for FY2024, which is 59.68% up from last year.
  • Cytokinetics' Non-Current Debt amounted to $158.7 million in Q3 2025, which was down 0.20% from $159.1 million recorded in Q2 2025.
  • In the past 5 years, Cytokinetics' Non-Current Debt registered a high of $159.1 million during Q2 2025, and its lowest value of $30.2 million during Q3 2021.
  • Over the past 3 years, Cytokinetics' median Non-Current Debt value was $92.0 million (recorded in 2025), while the average stood at $90.1 million.
  • Its Non-Current Debt has fluctuated over the past 5 years, first slumped by 34.23% in 2021, then soared by 110.39% in 2022.
  • Cytokinetics' Non-Current Debt (Quarterly) stood at $47.4 million in 2021, then spiked by 34.71% to $63.8 million in 2022, then dropped by 8.50% to $58.4 million in 2023, then surged by 59.68% to $93.2 million in 2024, then soared by 70.66% to $158.7 million in 2025.
  • Its Non-Current Debt stands at $158.7 million for Q3 2025, versus $159.1 million for Q2 2025 and $92.0 million for Q1 2025.